Q
QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,427 signal articles · 136 in last 24h · 153,916 total before filter · latest 38m ago
136last 24h
869last 7d
142● bullish (7d)
101● bearish (7d)
214publishers
AllMacro209Earnings103M&A123Regulatory22Product21Analyst14
Sentiment:bullishneutralbearishshow all (incl. clickbait)
Investing.com1h agoneutral
Newsmax pressures DOJ to block Fox’s $22B Roku deal, Semafor reports

Investing.com -- Newsmax Inc (NYSE:NMAX) Chief Executive Chris Ruddy is pressing the Justice Department to block Fox Corp's (NASDAQ:FOX) proposed $22 billion acquisition of Roku Inc (NASDAQ:ROKU), leveraging White House access to escalate a regulatory battle against his larger rival.

Meta's stock surges as it moves from AI laggard to leader
Yahoo Finance Video1h agobullishVIDEO
Meta's stock surges as it moves from AI laggard to leader

KeyBanc Capital Markets Managing Director Justin Patterson joins Market Domination's Brooke DiPalma to discuss the resurgence of Meta (META) stock and how its upcoming product releases could usher it into the next phase of growth.

9-24-2026: Trump-Xi Summit, Surging Yields + AI Disruption Trade Fears
NYSE1h agoneutralVIDEO
9-24-2026: Trump-Xi Summit, Surging Yields + AI Disruption Trade Fears

Michael Reinking, Senior Market Strategist at the NYSE, reviews a dynamic week in which the S&P 500 held modest gains despite poor breadth and surging Treasury yields. Strong flash PMI data fueled inflation worries, while Meta's new AI agent Muse sparked a fresh disruption trade across wealth managers, brokerages, and travel names. Oil prices swung sharply on shifting Middle East diplomacy headlines all week. President Trump and Xi Jinping met at the White House extending their trade truce through January while easing broader market jitters. Looking ahead, next week brings PCE inflation data, key earnings from Nike and Micron, and OpenAI's anticipated Dev Day.

Investing.com2h agoneutral
OpenAI’s former head of data centers joins Nvidia

Investing.com -- Chris Malone, OpenAI's former head of data centers, joined Nvidia as vice president of the company's DSX Platform this month, according to his LinkedIn profile. The DSX division helps customers design and build AI data centers according to Nvidia's specifications.

A Guide to Owning Bonds When They Are Selling Off
The Wall Street Journal2h agobearish
A Guide to Owning Bonds When They Are Selling Off

A bond-market rout pushed the 10-year Treasury yield to the highest since 2007, but it doesn’t erase the value of fixed income in a diversified portfolio. Over 80% of the global bond market now yields above 4%, according to BlackRock. The asset manager says the average yield in a bond portfolio it tracks has more than doubled from five years earlier.

Trump Stance on AI an 'Extremely Naive Position,' Says Sen. Michael Bennet
Bloomberg3h agoneutralVIDEO
Trump Stance on AI an 'Extremely Naive Position,' Says Sen. Michael Bennet

Democrat Senator from Colorado Michael Bennet said that the American people want a president more focused on high interest rates and fuel prices rather 'than throwing reporters out of the White House and the glamour of his dinner with the president of China.' Bennet also weighed in on talks around AI safety and said that the Presidents decision to not enact guardrails is an 'extremely naive position.'

The Short-Duration Bond ETF Boom Post Fed Hike
etf.com3h agoneutral
The Short-Duration Bond ETF Boom Post Fed Hike

<p>The Fed just hiked rates and signaled more to come. Fixed-income ETFs have already pulled in about $460 billion year to date, more than the $435 billion they gathered in all of 2025, and Treasury products led by ultra-short funds are taking the largest share. Leading the charge is a single fund that has quietly ballooned past $110 billion in assets. Here's why investors are hiding in short-duration bonds, and the ETFs at the center of the move.</p>

Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine
Benzinga3h agobearish
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine

Merck & Co. Inc. (NYSE:MRK) on Thursday announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). DME is a serious eye complication of diabetes where high blood sugar damages tiny retinal blood vessels, causing them to leak fluid into the macula (the central part of the retina responsible for sharp vision) and making it swell. BRUNELLO is the first of two Phase 2b/3 trials evaluating remigromig (MK-3000, formerly EYE103), an investigational